Latest news

• FDA lifts partial clinical hold on bluebird bio’s sickle cell gene therapy studies

  The company’s Skysona (elivaldogene autotemcel) gene therapy was granted accelerated approval by the FDA in September this year to slow the progression of neurologic dysfunction in boys four to 17 ... The prior month, bluebird’s Zynteglo

• bluebird bio sells Rare Pediatric Disease Priority Review Voucher

  bluebird bio received two PRVs upon the FDA approvals of Zynteglo (betibeglogene autotemcel) for the treatment of beta-thalassaemia (beta-thal) in adult and paediatric patients requiring regular red blood cell ... transfusions, as well as Skysona

• bluebird bio’s Skysona approved by FDA to treat cerebral adrenoleukodystrophy

  bluebird bio’s Skysona (elivaldogene autotemcel, also known as eli-cel) gene therapy has been granted accelerated approval by the US Food and Drug Association (FDA) to slow the progression of

• bluebird bio reveals plans to launch two gene therapies

  bluebird bio has reported its financial results and business highlights for the second quarter of 2022, in which the company revealed the anticipated launch of both betibeglogene autotemcel (beti-cel) and ... elivaldogene autotemcel (eli-cel) gene

• bluebird bio maintains its focus on gene therapy opportunities during structural changes

  It is also concentrating on the potential submission of a biologics license application (BLA) for the lovotibeglogene autotemcel (lovo-cel) gene therapy for sickle cell disease, planned for the first quarter ... Indeed, if approved, betibeglogene